Research ExplorerPublicationsPrasugrel as opposed to clopidogrel improves endothelial nit...

Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris. A randomized controlled trial

Standard

Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris. A randomized controlled trial. / Rudolph, Tanja K; Fuchs, Alexander; Klinke, Anna; Schlichting, Andrea; Friedrichs, Kai; Hellmich, Martin; Mollenhauer, Martin; Schwedhelm, Edzard; Baldus, Stephan; Rudolph, Volker.

In: INT J CARDIOL, Vol. 248, 01.12.2017, p. 7-13.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rudolph, TK, Fuchs, A, Klinke, A, Schlichting, A, Friedrichs, K, Hellmich, M, Mollenhauer, M, Schwedhelm, E, Baldus, S & Rudolph, V 2017, 'Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris. A randomized controlled trial', INT J CARDIOL, vol. 248, pp. 7-13. https://doi.org/10.1016/j.ijcard.2017.06.099

APA

Rudolph, T. K., Fuchs, A., Klinke, A., Schlichting, A., Friedrichs, K., Hellmich, M., Mollenhauer, M., Schwedhelm, E., Baldus, S., & Rudolph, V. (2017). Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris. A randomized controlled trial. INT J CARDIOL, 248, 7-13. https://doi.org/10.1016/j.ijcard.2017.06.099

Vancouver

Rudolph TK, Fuchs A, Klinke A, Schlichting A, Friedrichs K, Hellmich M et al. Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris. A randomized controlled trial. INT J CARDIOL. 2017 Dec 1;248:7-13. https://doi.org/10.1016/j.ijcard.2017.06.099

Bibtex

@article{8426ae6d79e941ec809fcfe883b8b3a0,
title = "Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris. A randomized controlled trial",
abstract = "BACKGROUND: Platelet inhibition has been linked to improved endothelial function, a prognostic factor in coronary artery disease. Whether prasugrel, a potent platelet inhibitor, affects endothelial function remains unknown.METHODS: This was a double-blind, randomized, active-controlled, parallel trial. Patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI) received either a daily dose of clopidogrel 75mg (n=23) or prasugrel 10mg (n=22). Flow-mediated dilation (FMD), circulating nitrate and nitrite, inflammatory markers and platelet-leukocyte aggregates (PLAs) were assessed the day after PCI and after 3months.RESULTS: Baseline patient demographics were well matched between treatment groups. Prasugrel led to a significant improvement of FMD after 3months (9.01±3.64% vs. 6.65±3.24%, p=0.001). In contrast, no significant change was observed in the clopidogrel group (7.21±2.84% vs. 6.30±2.97%, p=0.187). Adjusted for baseline FMD, hyperlipidemia and statin use, the treatment effect on change in FMD favoured prasugrel by an absolute 1.97% (95% CI 0.29% to 3.66%, p=0.023). A significant reduction of plasma hsCRP, myeloperoxidase and neutrophil elastase and an increase of nitrate levels were noted in both treatment arms. Interestingly, only prasugrel significantly reduced sCD40 ligand and RANTES and increased nitrite levels. Prasugrel reduced the ADP-stimulated increase in PLAs by 40% (IR: 82 to 13), whereas clopidogrel revealed no such effect (1% increase (IR: 13 to 50) (p=0.01).CONCLUSION: Prasugrel exhibits beneficial mid-term effects on endothelial nitric oxide bioavailability and inflammatory markers. (EudraCT number: 2009-015406-19).",
keywords = "Journal Article",
author = "Rudolph, {Tanja K} and Alexander Fuchs and Anna Klinke and Andrea Schlichting and Kai Friedrichs and Martin Hellmich and Martin Mollenhauer and Edzard Schwedhelm and Stephan Baldus and Volker Rudolph",
note = "Copyright {\textcopyright} 2017 Elsevier Ireland Ltd. All rights reserved.",
year = "2017",
month = dec,
day = "1",
doi = "10.1016/j.ijcard.2017.06.099",
language = "English",
volume = "248",
pages = "7--13",
journal = "INT J CARDIOL",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris. A randomized controlled trial

AU - Rudolph, Tanja K

AU - Fuchs, Alexander

AU - Klinke, Anna

AU - Schlichting, Andrea

AU - Friedrichs, Kai

AU - Hellmich, Martin

AU - Mollenhauer, Martin

AU - Schwedhelm, Edzard

AU - Baldus, Stephan

AU - Rudolph, Volker

N1 - Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - BACKGROUND: Platelet inhibition has been linked to improved endothelial function, a prognostic factor in coronary artery disease. Whether prasugrel, a potent platelet inhibitor, affects endothelial function remains unknown.METHODS: This was a double-blind, randomized, active-controlled, parallel trial. Patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI) received either a daily dose of clopidogrel 75mg (n=23) or prasugrel 10mg (n=22). Flow-mediated dilation (FMD), circulating nitrate and nitrite, inflammatory markers and platelet-leukocyte aggregates (PLAs) were assessed the day after PCI and after 3months.RESULTS: Baseline patient demographics were well matched between treatment groups. Prasugrel led to a significant improvement of FMD after 3months (9.01±3.64% vs. 6.65±3.24%, p=0.001). In contrast, no significant change was observed in the clopidogrel group (7.21±2.84% vs. 6.30±2.97%, p=0.187). Adjusted for baseline FMD, hyperlipidemia and statin use, the treatment effect on change in FMD favoured prasugrel by an absolute 1.97% (95% CI 0.29% to 3.66%, p=0.023). A significant reduction of plasma hsCRP, myeloperoxidase and neutrophil elastase and an increase of nitrate levels were noted in both treatment arms. Interestingly, only prasugrel significantly reduced sCD40 ligand and RANTES and increased nitrite levels. Prasugrel reduced the ADP-stimulated increase in PLAs by 40% (IR: 82 to 13), whereas clopidogrel revealed no such effect (1% increase (IR: 13 to 50) (p=0.01).CONCLUSION: Prasugrel exhibits beneficial mid-term effects on endothelial nitric oxide bioavailability and inflammatory markers. (EudraCT number: 2009-015406-19).

AB - BACKGROUND: Platelet inhibition has been linked to improved endothelial function, a prognostic factor in coronary artery disease. Whether prasugrel, a potent platelet inhibitor, affects endothelial function remains unknown.METHODS: This was a double-blind, randomized, active-controlled, parallel trial. Patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI) received either a daily dose of clopidogrel 75mg (n=23) or prasugrel 10mg (n=22). Flow-mediated dilation (FMD), circulating nitrate and nitrite, inflammatory markers and platelet-leukocyte aggregates (PLAs) were assessed the day after PCI and after 3months.RESULTS: Baseline patient demographics were well matched between treatment groups. Prasugrel led to a significant improvement of FMD after 3months (9.01±3.64% vs. 6.65±3.24%, p=0.001). In contrast, no significant change was observed in the clopidogrel group (7.21±2.84% vs. 6.30±2.97%, p=0.187). Adjusted for baseline FMD, hyperlipidemia and statin use, the treatment effect on change in FMD favoured prasugrel by an absolute 1.97% (95% CI 0.29% to 3.66%, p=0.023). A significant reduction of plasma hsCRP, myeloperoxidase and neutrophil elastase and an increase of nitrate levels were noted in both treatment arms. Interestingly, only prasugrel significantly reduced sCD40 ligand and RANTES and increased nitrite levels. Prasugrel reduced the ADP-stimulated increase in PLAs by 40% (IR: 82 to 13), whereas clopidogrel revealed no such effect (1% increase (IR: 13 to 50) (p=0.01).CONCLUSION: Prasugrel exhibits beneficial mid-term effects on endothelial nitric oxide bioavailability and inflammatory markers. (EudraCT number: 2009-015406-19).

KW - Journal Article

U2 - 10.1016/j.ijcard.2017.06.099

DO - 10.1016/j.ijcard.2017.06.099

M3 - SCORING: Journal article

C2 - 28709700

VL - 248

SP - 7

EP - 13

JO - INT J CARDIOL

JF - INT J CARDIOL

SN - 0167-5273

ER -